Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 257695, 7 pages
http://dx.doi.org/10.1155/2012/257695
Review Article

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

1Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, UNIFESP/EPM, Rua Botucatu, 04023-900 Vila Clementino, SP, Brazil
2Departamento de Ciências Biológicas, UNIFESP, 09972-270, Diadema, SP, Brazil

Received 4 November 2011; Accepted 28 December 2011

Academic Editor: Mohamad Mohty

Copyright © 2012 Fabricio de Carvalho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bangham, “Auspicious antigens,” Nature Reviews Cancer, vol. 5, article 499, 2005. View at Google Scholar
  2. E. Gilboa, “The promise of cancer vaccines,” Nature Reviews Cancer, vol. 4, no. 5, pp. 401–411, 2004. View at Google Scholar · View at Scopus
  3. R. T. Prehn and J. M. Main, “Immunity to methylcholanthrene-induced sarcomas,” Journal of the National Cancer Institute, vol. 18, no. 6, pp. 769–778, 1957. View at Google Scholar · View at Scopus
  4. G. Klein, H. O. Sjogren, E. Klein, and K. E. Hellstrom, “Demonstration of resistance against methylcholanthrene-induced sarcomas,” Cancer Research, vol. 20, pp. 1561–1572, 1960. View at Google Scholar
  5. T. Utsunomiya, H. Inoue, F. Tanaka et al., “Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma,” Annals of Surgical Oncology, vol. 11, no. 10, pp. 934–940, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. O. Hofmann, O. L. Caballero, B. J. Stevenson et al., “Genome-wide analysis of cancer/testis gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20422–20427, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. N. Akers, K. Odunsi, and A. R. Karpf, “Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy,” Future Oncology, vol. 6, no. 5, pp. 717–732, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. R. Peng, H. S. Chen, D. C. Mou et al., “Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters,” Cancer Letters, vol. 219, no. 2, pp. 223–232, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. F. F. Costa, K. Le Blanc, and B. Brodin, “Concise review: cancer/testis antigens, stem cells, and cancer,” Stem Cells, vol. 25, no. 3, pp. 707–711, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Y. T. Chen, A. Chadburn, P. Lee et al., “Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3093–3098, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Van Der Bruggen, C. Traversari, P. Chomez et al., “A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma,” Science, vol. 254, no. 5038, pp. 1643–1647, 1991. View at Google Scholar · View at Scopus
  12. C. De Smet, C. Lurquin, E. De Plaen et al., “Genes coding for melanoma antigens recognised by cytolytic T lymphocytes,” Eye, vol. 11, no. 2, pp. 243–248, 1997. View at Google Scholar · View at Scopus
  13. P. Chaux, R. Luiten, N. Demotte et al., “Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1,” Journal of Immunology, vol. 163, no. 5, pp. 2928–2936, 1999. View at Google Scholar · View at Scopus
  14. A. A. Jungbluth, S. Ely, M. DiLiberto et al., “The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation,” Blood, vol. 106, no. 1, pp. 167–174, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. J. Scanlan, A. J. Simpson, and L. J. Old, “The cancer/testis genes: review, standardization, and commentary,” Cancer Immunity, vol. 4, article 1, 2004. View at Google Scholar · View at Scopus
  16. K. H. Shain, D. N. Yarde, M. B. Meads et al., “β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation,” Cancer Research, vol. 69, no. 3, pp. 1009–1015, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. I. Su, T. Wiltshire, S. Batalov et al., “A gene atlas of the mouse and human protein-encoding transcriptomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 16, pp. 6062–6067, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Condomines, D. Hose, P. Raynaud et al., “Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis,” Journal of Immunology, vol. 178, no. 5, pp. 3307–3315, 2007. View at Google Scholar · View at Scopus
  19. H. J. Cho, O. L. Caballero, S. Gnjatic et al., “Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6),” Cancer Immunity, vol. 6, article 12, 2006. View at Google Scholar · View at Scopus
  20. C. A. Glazer, I. M. Smith, M. F. Ochs et al., “Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC,” PLoS One, vol. 4, no. 12, Article ID e8189, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. O. L. Caballero and Y. T. Chen, “Cancer/testis (CT) antigens: potential targets for immunotherapy,” Cancer Science, vol. 100, no. 11, pp. 2014–2021, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old, “Cancer/testis antigens, gametogenesis and cancer,” Nature Reviews Cancer, vol. 5, no. 8, pp. 615–625, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. B. J. Stevenson, C. Iseli, S. Panji et al., “Rapid evolution of cancer/testis genes on the X chromosome,” BMC Genomics, vol. 8, article 129, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. F. de Carvalho, E. T. Costa, A. A. Camargo et al., “Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines,” PLoS One, vol. 6, no. 11, Article ID e27707, 2011. View at Publisher · View at Google Scholar · View at PubMed
  25. R. B. Parmigiani, F. Bettoni, M. D. Vibranovski et al., “Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18066–18071, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. P. F. Robbins, R. A. Morgan, S. A. Feldman et al., “Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 917–924, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. J. Yuan, M. Adamow, B. A. Ginsberg et al., “Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. 16723–16728, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. L. Nadav, B. Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger, “The generation and regulation of functional diversity of malignant plasma cells,” Cancer Research, vol. 66, no. 17, pp. 8608–8616, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. G. M. Dores, O. Landgren, K. A. McGlynn, R. E. Curtis, M. S. Linet, and S. S. Devesa, “Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004,” British Journal of Haematology, vol. 144, no. 1, pp. 86–94, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. R. Fonseca, P. L. Bergsagel, J. Drach et al., “International Myeloma Working Group molecular classification of multiple myeloma: spotlight review,” Leukemia, vol. 23, no. 12, pp. 2210–2221, 2009. View at Google Scholar · View at Scopus
  31. Q. B. Li, Z. C. Chen, Y. You, and P. Zou, “Small interfering RNA of cyclooxygenase-2 induces growth inhibition and apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells,” Acta Pharmacologica Sinica, vol. 28, no. 7, pp. 1031–1036, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. D. J. White, N. Paul, D. A. Macdonald, R. M. Meyer, and L. E. Shepherd, “Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY. 11 trial,” Current Oncology, vol. 14, no. 2, pp. 61–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Kumar, “Multiple myeloma—current issues and controversies,” Cancer Treatment Reviews, vol. 36, supplement 2, pp. S3–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Pabst, J. Zustin, F. Jacobsen et al., “Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma,” Experimental and Molecular Pathology, vol. 89, no. 2, pp. 175–181, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. K. C. Anderson, M. Alsina, W. Bensinger et al., “Multiple myeloma,” Journal of the National Comprehensive Cancer Network, vol. 9, no. 10, pp. 1146–1183, 2011. View at Google Scholar
  36. H. Ludwig, “Advances in biology and treatment of multiple myeloma,” Annals of Oncology, vol. 16, no. 2, pp. ii106–ii112, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson, “New drugs for myeloma,” Oncologist, vol. 12, no. 6, pp. 664–689, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. A. Kyle and S. V. Rajkumar, “Multiple myeloma,” Blood, vol. 111, no. 6, pp. 2962–2972, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. Broyl, D. Hose, H. Lokhorst et al., “Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients,” Blood, vol. 116, no. 14, pp. 2543–2553, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. K. Mahtouk, J. Moreaux, D. Hose et al., “Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays,” BMC Cancer, vol. 10, article 198, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. I. M. Ghobrial and A. K. Stewart, “ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?” American Society of Hematology Education Program Book, pp. 587–589, 2009. View at Google Scholar · View at Scopus
  42. Z. Duan, Y. Duan, D. E. Lamendola et al., “Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicinresistant human cancer cell lines,” Clinical Cancer Research, vol. 9, no. 7, pp. 2778–2785, 2003. View at Google Scholar · View at Scopus
  43. T. Suzuki, K. Yoshida, Y. Wada et al., “Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer,” Oncology Reports, vol. 18, no. 2, pp. 329–336, 2007. View at Google Scholar · View at Scopus
  44. M. van Duin, A. Broyl, Y. de Knegt et al., “Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy,” Haematologica, vol. 96, no. 11, pp. 1662–1669, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. D. Atanackovic, Y. Hildebrandt, A. Jadczak et al., “Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells,” Haematologica, vol. 95, no. 5, pp. 785–793, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. B. Yang, S. M. O'Herrin, J. Wu et al., “MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines,” Cancer Research, vol. 67, no. 20, pp. 9954–9962, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. B. Yang, S. O'Herrin, J. Wu et al., “Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo,” Journal of Investigative Dermatology, vol. 127, no. 2, pp. 267–275, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. P. Chomez, O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas, “An overview of the MAGE gene family with the identification of all human members of the family,” Cancer Research, vol. 61, no. 14, pp. 5544–5551, 2001. View at Google Scholar · View at Scopus
  49. P. A. Barker and A. Salehi, “The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease,” Journal of Neuroscience Research, vol. 67, no. 6, pp. 705–712, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. V. C. Andrade, A. L. Vettore, R. S. Felix et al., “Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients,” Cancer Immunity, vol. 8, article 2, 2008. View at Google Scholar · View at Scopus
  51. O. Goodyear, K. Piper, N. Khan et al., “CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden,” Blood, vol. 106, no. 13, pp. 4217–4224, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. Y. T. Chen, A. O. Güre, S. Tsang et al., “Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 6919–6923, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Lucas, C. De Smet, K. C. Arden et al., “Identification of a new MAGE gene with tumor-specific expression by representational difference analysis,” Cancer Research, vol. 58, no. 4, pp. 743–752, 1998. View at Google Scholar · View at Scopus
  54. D. A. Chitale, A. A. Jungbluth, D. S. Marshall et al., “Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray,” Modern Pathology, vol. 18, no. 1, pp. 119–126, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. N. Nuber, A. Curioni-Fontecedro, C. Mattera et al., “Fine analysis of spontaneous MAGE-C1/CT7—specific immunity in melanoma patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 34, pp. 15187–15192, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. V. Dhodapkar, K. Osman, J. Teruya-Feldstein et al., “Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease,” Cancer Immun, vol. 3, article 9, 2003. View at Google Scholar · View at Scopus
  57. M. Tinguely, B. Jenni, A. Knights et al., “MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome,” Cancer Science, vol. 99, no. 4, pp. 720–725, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. Curioni-Fontecedro, A. J. Knights, M. Tinguely et al., “MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma,” Leukemia, vol. 22, no. 8, pp. 1646–1648, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. D. Atanackovic, T. Luetkens, Y. Hildebrandt et al., “Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma,” Clinical Cancer Research, vol. 15, no. 4, pp. 1343–1352, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. N. Lendvai, S. Gnjatic, E. Ritter et al., “Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients,” Cancer Immunity, vol. 10, article 4, 2010. View at Google Scholar · View at Scopus
  61. L. D. Anderson Jr., D. R. Cook, T. N. Yamamoto, C. Berger, D. G. Maloney, and S. R. Riddell, “Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma,” Cancer Immunology, Immunotherapy, vol. 60, no. 7, pp. 985–997, 2011. View at Publisher · View at Google Scholar · View at PubMed